«

»

ASCO Special Article: Use of pharmacologic interventions for breast cancer risk reduction: ASCO practice guideline

by jmiller on July 15, 2013

This early release article (JCO early release) includes the specific risks and benefits associated with each chemopreventive agent.  In women at increased risk of BC age >35 years, tamoxifen (20 mg per day for 5 years) should be discussed as an option to reduce the risk of ER – positive BC.  In postmenopausal women, raloxifene (60 mg per day for 5 years) should also be discussed as options for BC risk reduction.   These guideline recommendations are for use by medical oncologists, surgical oncologists, gynecologists, primary care physicians, and general practitioners.  Click here to read full-text.

Leave a Reply

Your email address will not be published.